NewsBenzingaOppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50 Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50 Benzinga 2026.09.23 12:08 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Crown Holdings, Raises Price Target to $139 Citigroup Maintains Buy on Capital One Financial, Raises Price Target to $285 10 Billion Reasons Meta’s Q3 EPS Could Shock You, and Not How You Think Citigroup Maintains Neutral on 3M, Raises Price Target to $188 How a SpaceX and Tesla Merger Would Reshape Musk’s AI Empire Citigroup Maintains Buy on SpaceX, Raises Price Target to $240
